How Wearables Are Changing Personal Health Tracking: 7 Things the Data Doesn't Tell You

This article examines the rapid expansion of consumer wearable health technology, tracing the global market's growth to $86.78 billion in 2025 with projections exceeding $231 billion by 2034, against a body of evidence revealing significant, often under-discussed accuracy limitations. It examines the FDA's February 2024 safety notice explicitly warning that no smartwatch or smart ring is authorized to measure blood glucose, and reviews Tobin and Jubran's foundational, repeatedly replicated finding that pulse oximetry inaccuracy in darker-skinned individuals has remained statistically unchanged across 32 years of device generations, alongside a December 2024 *JAMA* paper describing this as a "wicked problem" requiring coordinated manufacturer, clinical, and regulatory action. It examines the documented clinical phenomenon of wearable-induced health anxiety, the real distinction between FDA-cleared medical-grade devices and consumer-grade wellness devices, and the emergence of AI-driven personalized health insights as the current frontier of this technology. The article concludes with an original argument about why wearable accuracy is not a single property a device either has or lacks, but a variable that shifts systematically depending on what is being measured, under what conditions, and on whose body — and offers a practical framework for using wearable data as a genuinely useful signal without mistaking it for a diagnosis.